Ludger Limited

Ludger Limited is a biotechnology company based at the Culham Science Centre near Oxford in the United Kingdom. Its business is centred on glycosylation, the process by which sugar structures are attached to proteins and other biomolecules. In biopharmaceutical manufacturing, glycosylation can affect a product's activity, stability, immunogenicity, consistency, and regulatory profile. Ludger develops analytical technology, laboratory products, and specialist services intended to help researchers and manufacturers characterise these glycan structures and control them during biopharmaceutical development and production. The company was founded in 1999 by Dr Daryl Ludger Fernandes. Its origins lie in glycoprofiling work conducted by Fernandes during his doctorate at the University of Oxford's Glycobiology Institute. Before establishing Ludger, Fernandes was involved in transferring related technology to Oxford GlycoSciences in the late 1980s. This background connected the company to the development and commercial application of analytical methods for studying glycans and glycoproteins. Ludger received UK government-backed development support early in its history. In 2000 it won a Smart award from the UK Department of Trade and Industry to develop technology for analysing glycans in biopharmaceuticals. In 2001, it received a DTI Link grant for a collaborative project with GlaxoSmithKline and the University of Oxford. The project focused on creating faster glycoanalysis methods, reflecting the importance of analytical speed and reproducibility in pharmaceutical research and manufacturing. The company's product portfolio includes kits and reagents for detailed analysis of both N-linked and O-linked glycans. These products are used with techniques including high-performance liquid chromatography and mass spectrometry. Ludger's analytical scope includes monosaccharide analysis, sialic-acid analysis, oligosaccharide profiling, and more detailed determination of glycan structures. Sialic-acid analysis can help distinguish relative levels of human and non-human sialylation, an issue relevant to the biological behaviour and development of glycoprotein medicines. Alongside products, Ludger provides contract glycosylation analysis for biopharmaceutical development and regulatory work. Its services can support preparation of technical evidence for submissions to agencies such as the United States Food and Drug Administration and the European Medicines Agency. The company also offers method development for glycoprofiling and training in analytical procedures. This combination of laboratory consumables, applied analytical services, and specialist training gives Ludger a business-to-business positioning rather than a consumer-facing brand profile. Ludger's practical role is therefore within the analytical and quality-control layer of the biopharmaceutical value chain. It does not primarily present itself as a drug developer or a manufacturer of finished medicines. Instead, it supplies tools and expertise used to understand the carbohydrate structures associated with biological products, to compare batches or processes, and to support development and regulatory documentation. Publicly available reference material identifies its research and manufacturing facilities at Culham Science Centre and describes its continuing specialisation in biopharmaceutical glycosylation measurement and control. Detailed information on ownership, financial performance, market share, product launch dates, and current management beyond the founder's identified leadership role is not established in the supplied sources.

Ludger Limited was established in 1999 by Dr Daryl Ludger Fernandes, whose scientific work had focused on glycoprofiling technology. Fernandes developed this technology during doctoral research at the Glycobiology Institute of the University of Oxford. The company's formation translated that academic and technical background into a specialised commercial enterprise serving biopharmaceutical research and manufacturing. The company's origins also reflect earlier technology-transfer activity. In the late 1980s, Fernandes was responsible for transferring related glycoprofiling technology to Oxford GlycoSciences. This experience provided a connection between academic glycobiology research and industrial use of analytical methods for glycoproteins and glycans. Ludger obtained public support for its early research programme. In 2000, one year after its foundation, the company won a Smart award from the UK Department of Trade and Industry. The award supported development of technology for glycoanalysis in biopharmaceuticals. In 2001, Ludger received a DTI Link grant for a collaborative research and development project with GlaxoSmithKline and the University of Oxford. The project sought to develop rapid glycoanalysis technology, addressing the need for efficient analytical methods in pharmaceutical development. The company's subsequent activities have concentrated on measurement and control of biopharmaceutical glycosylation. Glycosylation is a complex attribute of many biological medicines, and the structures of attached glycans can vary according to the molecule, cell system, production process, and purification conditions. Analytical characterisation is consequently important for development, comparability, quality control, and regulatory support. Ludger's stated scope includes the analysis of N-linked and O-linked glycans using chromatography and mass spectrometry. Its business developed around two complementary areas. The first is the supply of kits and reagents for laboratory glycan analysis. These tools support several stages of glycoprofiling, including monosaccharide measurement, sialic-acid analysis, oligosaccharide profiling, and detailed structural analysis. The second is the provision of specialist services. Ludger performs contract glycosylation analysis, develops glycoprofiling methods, and provides training in biopharmaceutical glycoprofiling procedures. The company's analytical work can be used in biopharmaceutical development and in preparation of evidence for regulatory submissions to the United States Food and Drug Administration and the European Medicines Agency. Ludger's research and manufacturing facilities are located at the Culham Science Centre in Oxfordshire. Its identity has remained that of a focused biotechnology company rather than a diversified pharmaceutical group. The available reference material does not document acquisitions, public listing, major changes of ownership, product discontinuations, or a change in the company's core specialisation. It describes Ludger as continuing to provide products and services for the characterisation and quality control of biopharmaceutical glycosylation. Information about later financial results, employee numbers, major customers, and detailed current corporate structure is not available in the supplied sources.

• 2001

  DTI Link collaborative research grant

  [1]Ludger Limiteden.wikipedia.org

  The company wins a DTI Link grant for a rapid glycoanalysis project conducted with GlaxoSmithKline and the University of Oxford.

• 2000

  UK DTI Smart award

  [1]Ludger Limiteden.wikipedia.org

  Ludger receives a Smart award from the UK Department of Trade and Industry to support development of biopharmaceutical glycoanalysis technology.

• 1999

  Ludger Limited is founded

  [1]Ludger Limiteden.wikipedia.org

  Dr Daryl Ludger Fernandes establishes the company to commercialise and develop glycoprofiling and biopharmaceutical glycosylation technologies.

A specialist biotechnology and analytical-services provider for glycosylation measurement, glycan characterisation, and quality control in biopharmaceutical development.

• Analytical biotechnology

  N-linked glycan analysis kits and reagents

  Products for preparing and analysing N-linked glycans associated with biopharmaceutical glycoproteins. The supplied reference identifies these offerings as part of Ludger's broader kit and reagent portfolio and indicates that analysis can be performed using chromatographic and mass-spectrometric methods. They are intended for detailed glycan characterisation and quality-control workflows.

• Analytical biotechnology

  O-linked glycan analysis kits and reagents

  Kits and reagents for studying O-linked glycans in biopharmaceutical samples. These products support laboratory workflows designed to determine glycan profiles and structures, complementing Ludger's N-linked glycan tools. Specific commercial product names and launch dates are not provided in the available reference material.

• Laboratory reagents and analytical tools

  Glycoprofiling analysis products

  A broader set of kits and reagents supporting monosaccharide analysis, sialic-acid analysis, oligosaccharide profiling, and detailed glycan structure analysis. The tools are positioned for biopharmaceutical research, development, and quality-control applications, with workflows compatible with HPLC and mass spectrometry.

1. 1Ludger Limiteden.wikipedia.org